A carregar...
Chronic lymphocytic leukemia at ASH 2017
At ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together with a manageable safety profile in relapsed/refractory settin...
Na minha lista:
| Publicado no: | Memo |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Vienna
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6006235/ https://ncbi.nlm.nih.gov/pubmed/29983825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-018-0414-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|